empagliflozin and bladder cancer risk

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
empagliflozin and bladder cancer risk	0.11	0.4	5256	26	37
empagliflozin	1.71	0.9	5050	22	13
and	1.77	0.8	6524	77	3
bladder	1.37	0.2	5057	2	7
cancer	0.09	0.5	2096	87	6
risk	0.65	0.8	4943	78	4

Keyword	CPC	PCC	Volume	Score
empagliflozin and bladder cancer risk	1.54	0.4	6234	93
dapagliflozin and bladder cancer	0.2	0.4	1190	78
empagliflozin urinary tract infection	1.1	0.7	7328	15
empagliflozin and kidney disease	1.71	0.7	2384	58
benefits and risks of empagliflozin	1.42	0.6	8169	75
dapagliflozin bladder cancer	0.1	0.1	5237	52
dapagliflozin and urinary tract infection	0.96	0.2	2211	96
dapagliflozin and kidney disease	1.15	0.8	997	72
dapagliflozin in patients with chronic	1.39	0.3	4411	58
dapagliflozin in patients with chronic kidney	1.75	0.2	7842	33
dapagliflozin and liver function	1.36	0.6	1727	39
dapagliflozin canagliflozin and empagliflozin	1.71	0.9	6246	87
dapagliflozin and kidney function	1.06	1	8528	4
clinical studies of dapagliflozin	1.69	0.9	9019	99
dapagliflozin and blood pressure	0.41	0.4	6196	70
dapagliflozin and glucose in urine	1.92	0.3	9906	54
dapagliflozin information for patients	1.99	0.2	8488	8
dapagliflozin and renal impairment	0.28	0.9	531	5
dapagliflozin side effects urinary	0.96	1	3676	96
can dapagliflozin cause kidney failure	0.89	0.5	9233	81
dapagliflozin effect on kidneys	1.74	0.8	1605	78
dapagliflozin for chronic kidney	1.33	0.8	3394	22
dapagliflozin and back pain	0.44	0.2	8901	70
dapagliflozin in chronic kidney disease	1	0.4	1898	27
dapagliflozin in renal failure	0.88	0.2	1402	77
patient information on dapagliflozin	0.75	0.9	8874	22